News

Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...
Hims & Hers Health: Significant Impact Of Partnership Termination With Novo Nordisk; Initiate With 'Sell'
I am initiating a 'sell' rating on Hims & Hers Health, with a fair value of $35 per share, due to imminent growth risks.
Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug
The loss of Novo’s involvement significantly dented investor confidence in Hims & Hers, plunging shares in the latter by 35% ...
Why Hims & Hers Health Stock Is Crashing Today
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
Hims & Hers: Devastating GLP-1 News Could Shatter Growth Narrative
Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.
These Stocks Moved the Most Today: Tesla, Hims & Hers, Wolfspeed, Super Micro, Fiserv, Northrop, Northern Trust, and More
Tesla shares rise sharply after the electric-vehicle company launched its highly anticipated robo-taxi service in Austin, ...
Novo sends Hims packing
Meanwhile, Novo had agreed supply deals with Hims and several of its bigger rivals. The idea was to give their existing ...